Recce scores US$2M deal from US Department of Defense for burn wound infections gel
Recce Pharmaceuticals Ltd has been funded to the tune of US$2M by the US Department of Defense to develop its R327G gel.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online